Previous 10 | Next 10 |
home / stock / mycof / mycof news
The company is developing molecules based on psilocybin to treat PTSD and also has an app for psychedelic after-care remote therapy. Mydecine is the first company in the world to complete an international legal export of dried magic mushrooms. The future for psychedelic-assisted t...
Any time you have an emerging sector like psychedelic medicine, where every week new players are going public, it’s hard to determine who has real substance, a real infrastructure and real potential. On June 22, 2021, Mydecine Innovations Group Inc. separated itself from the ...
DENVER, June 24, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative ...
DENVER, June 23, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative ...
DENVER, June 16, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative ...
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) reports that its R&D team has discovered over 40 compounds with pharmacological potential in mushrooms. Mydecine said that it has screened over 25 mushroom species, including various varieties of p. cubensis, and...
DENVER, June 08, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative ...
DENVER, June 03, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative ...
Mydecine Innovations (MYCOF) has received approval from Health Canada to expand its cultivation capabilities at the company's Canadian Current Good Manufacturing Practice ((cGMP)) facility at Applied Pharmaceutical Innovation ((API)).Under the new guidance from Health Canada, Mydecine will be...
DENVER, May 25, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-so...
News, Short Squeeze, Breakout and More Instantly...
(TheNewswire) Vancouver, British Columbia, July 5, 2024— TheNewswire – Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) is pleased to confirm that further to its news release dated June 13, 2024, ...
(TheNewswire) Vancouver, British Columbia, May 31, 2024 - TheNewswire - Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) provides this update on the status of a management cease trade order granted on May 2...
(TheNewswire) Vancouver, British Columbia – TheNewswire - May 16, 2024— Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) provides this update on the status of a management cease trade order gr...